STOK
Stoke Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$27.68-4.72%
Price as of Jul 20, 2026
STOK profitability
Stoke Therapeutics, Inc. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 90.4%
- EBITDA margin
- -511.5%
- EBIT margin
- -577.5%
- Net margin
- -529.2%
- Free cash flow margin
- -460.4%
Returns
- Return on equity
- -43.0%
- Return on assets
- -38.3%
- Return on invested capital
- -46.5%
- Asset turnover
- 0.07x
Cash efficiency
- Cash from operations
- -$146.8M
- Cash per share
- $5.52
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.